← All indications
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Subtype terms (5)
More specific conditions that are subtypes of Stomatitis in the MeSH hierarchy.
- Stevens-Johnson Syndrome
21 drugs (18 approved, 3 experimental)
- Stomatitis, Aphthous
39 drugs (19 approved, 20 experimental)
- Stomatitis, Denture
7 drugs (5 approved, 2 experimental)
- Stomatitis, Herpetic
7 drugs (5 approved, 2 experimental)
- Vesicular Stomatitis
Drugs by status
Approved for this indication (2)
Phase 4 trials (16)
Phase 3 trials (20)
Phase 2 trials (46)
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (13)
- Sun Pharmaceuticals
- University of Roma La Sapienza
- Jiangmen Central Hospital
- Riyadh Colleges of Dentistry and Pharmacy
- University of Copenhagen
- University of Naples Frederico II
- King Faisal Specialist Hospital
- Sun Yat-Sen University
- PharPoint Research, Inc.
- Shanxi Zhendong pharmaceutical Co. LTD.
- Danish University
- People's Liberation Army of China
- Midatech Pharma
Organization Involved with Phase 3 Indications (46)
- Swedish Orphan Biovitrum
- McNeil
- Amgen
- Novartis
- Angelini
- Biotec Pharmacon ASA
- Endo Pharmaceuticals
- Daewoong Pharmaceutical Co. LTD.
- Soligenix
- British Columbia Cancer Agency
- National Cancer Institute (NCI)
- Cairo University
- Centre Leon Berard
- First People's Hospital of Foshan
- Guangzhou Medical University
- Medical College of Wisconsin
- Nanjing Medical University
- Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
- Radiation Therapy Oncology Group
- University of Leipzig
- Mayo Clinic
- Comprehensive Support Project for Oncology Research
- University of California, Los Angeles
- University of Connecticut
- All India Institute of Medical Sciences
- Galera Therapeutics
- MNJ Cancer Hospital Hyderabad
- University of Angers
- Centro Universitário
- Tianjin Medical University
- +16 more
Organization Involved with Phase 2 Indications (90)
- Alizyme
- DuPont
- RxKinetix
- CuraGen
- Pfizer
- Catalysis SL
- Exsulin Corporation
- Indena S.p.A
- Izun Pharma Ltd
- Mucosal Therapeutics
- Valerio
- Oral Defense, LLC
- SciClone Pharmaceuticals
- Spherium Biomed
- Sponsor GmbH
- Access Pharmaceuticals, Inc.
- EpicentRx, Inc.
- Otsuka
- Sucampo
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institute of Nursing Research (NINR)
- Shahid Beheshti University of Medical Sciences
- Alexandria University
- China Academy of Chinese Medical Sciences
- Harvard University
- University of Washington
- Istituto Oncologico Veneto IRCCS
- Mashhad University of Medical Sciences
- +60 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (17)
- Bitop AG
- The Christie NHS Foundation Trust
- National Cancer Institute, Egypt
- Children's Cancer and Leukaemia Group
- University of London
- New York University
- Sheffield Hallam University
- Universitat Internacional de Catalunya
- University of Manchester
- Fujian Medical University
- Taipei Medical University
- State University of New York, Buffalo
- Ben Gurion University
- Department of Veteran Affairs
- Oral Medicine & Periodontology department
- Federico Gomez Children's Hospital of Mexico
- National Institute of Pediatrics